牛牛AI助理已提取核心訊息
On March 7, 2024, Tharimmune, Inc., a Delaware-incorporated biotechnology company, filed a Form 8-K with the Securities and Exchange Commission to report an amendment to its Bylaws. The amendment, approved by the company's board of directors, revises the quorum requirement for stockholder meetings. Previously, a majority of the stockholders needed to be present or represented by proxy for a meeting to proceed. The new amendment lowers this requirement to one-third of the stockholders. The full text of the amendment is included as Exhibit 3.1 in the filing. Tharimmune, which is listed on The Nasdaq Stock Market under the symbol THAR, is classified as an emerging growth company.
On March 7, 2024, Tharimmune, Inc., a Delaware-incorporated biotechnology company, filed a Form 8-K with the Securities and Exchange Commission to report an amendment to its Bylaws. The amendment, approved by the company's board of directors, revises the quorum requirement for stockholder meetings. Previously, a majority of the stockholders needed to be present or represented by proxy for a meeting to proceed. The new amendment lowers this requirement to one-third of the stockholders. The full text of the amendment is included as Exhibit 3.1 in the filing. Tharimmune, which is listed on The Nasdaq Stock Market under the symbol THAR, is classified as an emerging growth company.
2024年3月7日，特拉華州註冊成立的生物技術公司Tharimmune, Inc. 向美國證券交易委員會提交了8-K表格，以報告其章程的修正案。該修正案經公司董事會批准，修訂了股東會議的法定人數要求。以前，大多數股東需要出席會議或由代理人代表才能舉行會議。新修正案將這一要求降低到三分之一的股東。修正案的全文作爲附錄3.1包含在文件中。Tharimmune在納斯達克股票市場上市，股票代碼爲THAR，被列爲新興成長型公司。
2024年3月7日，特拉華州註冊成立的生物技術公司Tharimmune, Inc. 向美國證券交易委員會提交了8-K表格，以報告其章程的修正案。該修正案經公司董事會批准，修訂了股東會議的法定人數要求。以前，大多數股東需要出席會議或由代理人代表才能舉行會議。新修正案將這一要求降低到三分之一的股東。修正案的全文作爲附錄3.1包含在文件中。Tharimmune在納斯達克股票市場上市，股票代碼爲THAR，被列爲新興成長型公司。
有用
沒用